HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Allergy & Immunology
Meta-analysis
EMA-approved biologics and JAK inhibitors show meaningful short-term EASI-75 responses in moderate-to-severe atopic dermatitis
Newer Eczema Drugs Clear Skin for Many, But Comparisons Are Tricky
This systematic review narratively synthesized randomized trials of EMA-approved systemic therapies for moderate-to-severe atopic dermatitis…
Seven eczema drugs helped 18% to 73% of adults reach clearer skin in 12 to 16 weeks. But trials varied too much to say which works best.
Frontiers
Oct 31, 2026
Dermatology
Sys. Review
Dupilumab, Lebrikizumab, Tralokinumab All Beat Placebo in Adolescent Eczema, No Clear Winner
New Treatments Show Promise for Severe Adolescent Atopic Dermatitis
This network meta-analysis of 642 adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis found that dupilumab, lebrikizumab, an…
New data shows that dupilumab, lebrikizumab, and tralokinumab may help teens with moderate to severe atopic dermatitis.
Oct 1, 2026
Dermatology
RCT
Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis
New analysis shows lebrikizumab helps clear skin faster than placebo for atopic dermatitis
This secondary analysis of two Phase 3 trials evaluated lebrikizumab 250 mg Q2W versus placebo in adults and adolescents with moderate-to-se…
A look at two major trials found lebrikizumab led to significantly better skin clearing than placebo in adults and adolescents with moderate…
May 21, 2026